Anthony J. Polverino - Dec 10, 2021 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role: Director
Signature: /s/ Anthony J. Polverino
Stock symbol: BCLI
Transactions as of: Dec 10, 2021
Transactions value $: $0
Form type: 4
Date filed: 12/10/2021, 07:03 PM
Previous filing: Sep 2, 2021
Next filing: Dec 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCLI	Common Stock	Award	$0	+2.22K	+13.97%	$0.00	18.1K	Dec 10, 2021	Direct	F1
transaction	BCLI	Common Stock	Award	$0	+2K	+11.06%	$0.00	20.1K	Dec 10, 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2021 until fully vested on the first anniversary of February 1, 2021, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.
F2	Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan . The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date.

Content

Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2021 until fully vested on the first anniversary of February 1, 2021, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan . The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date.